FDA Approves Daiichi Sankyo’s NOAC

The FDA recently approved the fourth new oral anticoagulant, Savaysa for use in non-valvular afib, DVT, and PE.  It is another factor Xa inhibitor.  Use in non-valvular afib requires renal function assessment prior to prescribing, as the drug is renally excreted.  Paradoxically, efficacy may be reduced in patients with better-than-normal renal function.